Current evaluation and management of anemia in patients with inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 11, Issue 1, 2017, Pages 19-32

  Martin, Julia ^a,b   Radeke, Heinfried H ^a,b   Dignass, Axel ^a,c   Stein, Jürgen ^a,b,d  

^a Interdisciplinary Crohn Colitis Centre Rhein Main   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c AGAPLESION MARKUS KRANKENHAUS   (Germany)

^d DGD Clinics Sachsenhausen   (Germany)

Author keywords

Anemia; diagnostic procedures; disease management; inflammatory bowel disease; iron deficiency

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN; IRON; PYRIDOXINE; VITAMIN D;

ANEMIA; ANEMIA OF CHRONIC DISEASE; ASYMPTOMATIC DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CLINICAL PRACTICE; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PERNICIOUS ANEMIA; PRACTICE GUIDELINE; PYRIDOXINE DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; VITAMIN D DEFICIENCY; BLOOD; COMPLICATION; INFLAMMATORY BOWEL DISEASES; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANEMIA; HUMANS; INFLAMMATORY BOWEL DISEASES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85003856401     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2017.1263566     Document Type: Review

References (116)

1. Fiorino G, Allocca M, Danese S., Anemia in inflammatory bowel disease:the opening of pandora’s box? Clin Gastroenterol Hepatol. 2015;13:1767–1769.
2. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease:epidemiology, diagnosis, and management. Ann Med. 2010;42:97–114.
3. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–130.
4. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.•• This paper highlights the current standards in the diagnosis and management of anemia in IBD patients and is the result of a European consensus process under the guidance of the European Crohn’s and Colitis Organization [ECCO].
5. WHO, UNICEF, UNU. Iron deficiency anemia:assessment, prevention and control. Report of a joint WHO/UNICEF/UNU consultation. Geneva:World Health Organization; 1998.
6. Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease:results from the European federation of crohn’s and ulcerative colitis association’s online survey. Eur J Gastroenterol Hepatol. 2014;26:1385–1391.
7. Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease:routine practice across nine European countries. Eur J Gastroenterol Hepatol. 2013;25:1456–1463.
8. Blumenstein I, Dignass A, Vollmer S, et al. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany:the German anaemIBD study. J Crohns Colitis. 2014;8:1308–1314.
9. Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol. 2011;46:304–309.
10. Voegtlin M, Vavricka SR, Schoepfer AM, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland:a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis. 2010;4:642–648.
11. Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia:a longitudinal 2-year follow-up study. Scand J Gastroenterol. 2013;48:1286–1293.
12. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:513–519.• This paper provides excellent data concerning the prevalence and management of anemia, showing that anemia is even more common in children than in adults.
13. Stein J, Dignass AU. Anaemia in the Elderly IBD Patient. Curr Treat Options Gastroenterol. 2015;13:308–318.
14. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries:a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936–945.• A recent analysis of the frequency of anemia in IBD patients in European countries.
15. Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15:4659–4665.
16. Rejler M, Tholstrup J, Andersson-Gare B, et al. Low prevalence of anemia in inflammatory bowel disease:a population-based study in Sweden. Scand J Gastroenterol. 2012;47:937–942.
17. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199–205.
18. Beutler E, Waalen J. The definition of anemia:what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107:1747–1750.
19. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
20. Walker AM, Szneke P, Bianchi LA, et al. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997;92:816–820.
21. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease:impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429–436.
22. Blanchet E, Beau P, Frat JP. [Bone marrow aplasia following dipyrone treatment in a patient with Crohn’s disease receiving long-term methotrexate]. Gastroenterol Clin Biol. 2004;28:502–503.
23. Danesi R, Del tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. 2004;36:703–704.
24. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol. 2013;26:104–113.
25. Loitsch SM, Diehl D, Hartmann F, et al. Impaired intestinal iron absorption in inflammatory bowel disease correlates with disease activity and markers of inflammation but is independent of disease location. Gastroenterology. 2011;140:S5–S5.
26. Sharma N, Begum J, Eksteen B, et al. Differential ferritin expression is associated with iron deficiency in coeliac disease. Eur J Gastroenterol Hepatol. 2009;21:794–804.
27. Johnson D, Bayele H, Johnston K, et al. Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett. 2004;573:195–201.
28. Cartwright GE, Lauritsen MA, Humphreys S, et al. The anemia associated with chronic infection. Science. 1946;103:72–73.
29. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023.• An up-to-date review providing the reader with a comprehensive overview of anemia of chronic disease.
30. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28:671–81,vi.
31. Zarychanski R, Houston DS. Anemia of chronic disease:a harmful disorder or an adaptive, beneficial response? Cmaj. 2008;179:333–337.•• On the basis of an extensive literature search, the authors demonstrated that, regardless of disease location in the ileum, Crohn’s disease without ileal resection did not increase the risk for vitamin B12 deficiency, and that serum vitamin B12 levels alone are probably insufficient to diagnose deficiency in asymptomatic patients.
32. Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease:prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis. 2014;20:1120–1128.• This very comprehensive review shows that vitamin B12 deficiency anemia is not uncommon after restorative proctocolectomy, and that it has negative effects on the patient’s quality of life.
33. M’Koma AE, Wise PE, Schwartz DA, et al. Prevalence and outcome of anemia after restorative proctocolectomy:a clinical literature review. Dis Colon Rectum. 2009;52:726–739.
34. Onal IK. Folate deficiency in Crohn’s disease. Scand J Gastroenterol. 2014;49:253–254.
35. Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol. 2013;48:1272–1277.
36. Meenan J, O’Hallinan E, Scott J, et al. Influence of sulfasalazine and olsalamine on colonic epithelial cell folate content in patients with ulcerative colitis. Inflamm Bowel Dis. 1996;2:163–167.
37. Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia:serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051–1055.
38. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease:from A to zinc. Inflamm Bowel Dis. 2012;18:1961–1981.
39. Devalia V, Hamilton MS, Molloy AM, et al. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166:496–513.
40. Del Pinto R, Pietropaoli D, Chandar AK, et al. Association between inflammatory bowel disease and vitamin D deficiency:a systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:2708–2717.
41. Veit LE, Maranda L, Fong J, et al. The vitamin D status in inflammatory bowel disease. Plos One. 2014;9:e101583.
42. Smith EM, Tangpricha V. Vitamin D and anemia:insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015;22:432–438.
43. Lac PT, Choi K, Liu IA, et al. The effects of changing vitamin D levels on anemia in chronic kidney disease patients:a retrospective cohort review. Clin Nephrol. 2010;74:25–32.
44. Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25:564–572.• This study demonstrates a regulatory role for vitamin D in iron homeostasis by identifying vitamin D response elements (VDREs) on the HAMP gene. It offers evidence that in vitro treatment of monocytes and hepatocytes with vitamin D suppresses hepcidin mRNA transcription, while in vivo vitamin D supplementation of healthy humans reduces serum hepcidin concentrations.
45. Michelazzo FB, Oliveira JM, Stefanello J, et al. The influence of vitamin A supplementation on iron status. Nutrients. 2013;5:4399–4413.
46. Da cunha MS, Siqueira EM, Trindade LS, et al. Vitamin A deficiency modulates iron metabolism via ineffective erythropoiesis. J Nutr Biochem. 2014;25:1035–1044.
47. Jiang S, Wang CX, Lan L, et al. Vitamin A deficiency aggravates iron deficiency by upregulating the expression of iron regulatory protein-2. Nutrition. 2012;28:281–287.
48. Soares-Mota M, Silva TA, Gomes LM, et al. High prevalence of vitamin A deficiency in Crohn’s disease patients according to serum retinol levels and the relative dose-response test. World J Gastroenterol. 2015;21:1614–1620.
49. Zimmermann MB, Biebinger R, Rohner F, et al. Vitamin A supplementation in children with poor vitamin A and iron status increases erythropoietin and hemoglobin concentrations without changing total body iron. Am J Clin Nutr. 2006;84:580–586.
50. Shoolingin-jordan PM, Al-daihan S, Alexeev D, et al. 5-Aminolevulinic acid synthase:mechanism, mutations and medicine. Biochim Biophys Acta. 2003;1647:361–366.
51. Maier C. [Megaloblastic vitamin B6 deficiency anemia in hemochromatosis]. Schweiz Med Wochenschr. 1957;87:1234–1235.
52. Yasuda H, Fujiwara N, Ishizaki Y, et al. Anemia attributed to vitamin B6 deficiency in post-pancreaticoduodenectomy patients. Pancreatology. 2015;15:81–83.
53. Hisano M, Suzuki R, Sago H, et al. Vitamin B6 deficiency and anemia in pregnancy. Eur J Clin Nutr. 2010;64:221–223.
54. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease:role of inflammation and correlation with acute phase reactants. Am J Gastroenterol. 2003;98:112–117.
55. Vagianos K, Bernstein CN. Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease:a one-year prospective follow-up study. Inflamm Bowel Dis. 2012;18:718–724.
56. Giannadaki E, Potamianos S, Roussomoustakaki M, et al. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol. 1997;92:1872–1874.
57. Lorber M, Schwartz LI, Wasserman LR. Association of antibody-coated red blood cells with ulcerative colitis; report of four cases. Am J Med. 1955;19:887–894.
58. Yates P, Macht LM, Williams NA, et al. Red cell autoantibody production by colonic mononuclear cells from a patient with ulcerative colitis and autoimmune haemolytic anaemia. Br J Haematol. 1992;82:753–756.
59. Park BS, Park S, Jin K, et al. Coombs negative autoimmune hemolytic anemia in Crohn’s disease. Am J Case Rep. 2014;15:550–553.
60. Plikat K, Rogler G, Scholmerich J. Coombs-positive autoimmune hemolytic anemia in Crohn’s disease. Eur J Gastroenterol Hepatol. 2005;17:661–666.
61. Wang Z, Zhou Y, Liu Y. Concurrent inflammatory bowel disease and myelodysplastic syndrome:report of nine new cases and a review of the literature. Dig Dis Sci. 2008;53:1929–1932.
62. Harewood GC, Loftus EV, Jr., Tefferi A, et al. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999;5:98–103.
63. Nakamura F, Watanabe T, Hori K, et al. Simultaneous occurrence of inflammatory bowel disease and myelodysplastic syndrome due to chromosomal abnormalities in bone marrow cells. Digestion. 2009;79:215–219.
64. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease:a prospective observational cohort study. Lancet. 2009;374:1617–1625.
65. Stein J, Connor SJ, Virgin G, et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016 Sep 21;22(35):7908-7925.
66. Vidarsdottir JB, Johannsdottir SE, Thorsdottir I, et al. A cross-sectional study on nutrient intake and status in inflammatory bowel disease patients. Nutr J 2016;15:61.
67. Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory bowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. 2016;40:405-411.
68. Zimmermann N, Krieger K, Loitsch SM, et al. Evidence of low micronutrient intake in patients with inflammatory bowel disease. Gastroenterology. 2011;140:S437-S437.
69. Gerasimidis K, McGrogan P, Edwards CA. The aetiology and impact of malnutrition in paediatric inflmmatory bowel disease. J Hum Nutr Diet. 2011;24:313-326.
70. Van assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3:special situations. J Crohns Colitis. 2013;7:1–33.
71. Stein J, Stier C, Raab H, et al. Review article:the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40:582–609.
72. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol. 2013;9:205–215.
73. Wish JB. Assessing iron status:beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl1):S4–8.
74. Heimpel H, Diem H, Nebe T. [Counting reticulocytes:new importance of an old method]. Med Klin (Munich). 2010;105:538–543.
75. Harms K, Kaiser T. Beyond soluble transferrin receptor:old challenges and new horizons. Best Pract Res Clin Endocrinol Metab. 2015;29:799–810.
76. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor, ferritin and TfR-F index in identification of latent iron deficiency. Eur J Haematol. 1998;60:135–137.
77. Junca J, Fernandez-aviles F, Oriol A, et al. The usefulness of the serum transferrin receptor in detecting iron deficiency in the anemia of chronic disorders. Haematologica. 1998;83:676–680.
78. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia:a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86:923–927.
79. Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease:a case-control study. Ann Gastroenterol. 2011;24:108–114.
80. Abitbol V, Borderie D, Polin V, et al. Diagnosis of iron deficiency in inflammatory bowel disease by transferrin receptor-ferritin index. Medicine (Baltimore). 2015;94:e1011.
81. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias:from M.M. Wintrobes’s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222–230.
82. Urrechaga E, Borque L, Escanero JF. Percentage of hypochromic erythrocytes as a potential marker of iron availability. Clin Chem Lab Med. 2012;50:685–687.
83. Parodi E, Giraudo MT, Davitto M, et al. Reticulocyte parameters:markers of early response to oral treatment in children with severe iron-deficiency anemia. J Pediatr Hematol Oncol. 2012;34:e249–52.
84. Dagg JH, Goldberg A, Lochhead A. Value of erythrocyte protoporphyrin in the diagnosis of latent iron deficiency (sideropenia). Br J Haematol. 1966;12:326–330.
85. Hastka J, Lasserre JJ, Schwarzbeck A, et al. Zinc protoporphyrin in anemia of chronic disorders. Blood. 1993;81:1200–1204.
86. Wiesenthal M, Dienethal A, Dignass AU, et al. Diagnostic accuracy of zinc protoporphyrin/heme ratio for screening of iron deficiency anaemia in patients with inflammatory bowel disease. Gastroenterology. 2014;146:S599–S599.
87. Wiesenthal M, Dignass A, Hartmann F, et al. Serum hepcidin levels predict intestinal iron absorption in IBD patients. J Crohns Colitis. 2014;8:S120–S120.
88. Martinelli M, Strisciuglio C, Alessandrella A, et al. Serum hepcidin and iron absorption in paediatric inflammatory bowel disease. J Crohns Colitis. 2016;10:566–574.
89. Carmel R. Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting:a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II. Am J Clin Nutr. 2011;94:348S–358S.
90. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease:results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–588.
91. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832–1843.
92. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults:a systematic review and meta-analysis. Plos One. 2015;10:e0117383.
93. Tay HS, Soiza RL. Systematic review and meta-analysis:what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging. 2015;32:149–158.
94. Kortman GA, Raffatellu M, Swinkels DW, et al. Nutritional iron turned inside out:intestinal stress from a gut microbial perspective. FEMS Microbiol Rev. 2014;38:1202–1234.
95. Jimenez K, Kulnigg-dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol (N Y). 2015;11:241–250.
96. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–1989.• The authors demonstrate that intestinal iron absorption can be maximized by administering lower oral iron doses and avoiding twice-daily dosing.
97. Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy:a pooled analysis of five randomized controlled trials. Haematologica. 2016;101:e6–7.•• Based on a retrospective pooled analysis of only five randomized controlled trials, this study shows for the first time that Hb on day 14 is an accurate predictor of sustained treatment response to long-term oral iron supplementation.
98. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51–60.
99. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992;42:1439–1452.
100. Schroeder SE, Reddy MB, Schalinske KL. Retinoic acid modulates hepatic iron homeostasis in rats by attenuating the RNA-binding activity of iron regulatory proteins. J Nutr. 2007;137:2686–2690.
101. Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease:a report of safety and efficacy. Int J Nephrol. 2013;2013:703038.
102. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. Jama. 2015;314:2062–2068.
103. (EMA). EMA. Assessment report for:Iron containing intravenous (IV) medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf 2013.
104. Ganzoni AM. [Intravenous iron-dextran:therapeutic and experimental possibilities]. Schweiz Med Wochenschr. 1970;100:301–303.
105. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-853 e1-2.•• This is a very large, randomized clinical trial with a prospective cost-effectiveness analysis showing ferric carboxymaltose to be more efficient than iron sucrose. The paper also presents a simplified formula for effectively calculating total iron dose.
106. Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460–1467.
107. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269–277.
108. Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–1233.
109. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368:149–160.
110. Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004655.
111. Selhub J, Morris MS, Jacques PF, et al. Folate-vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency. Am J Clin Nutr. 2009;89:702S–6S.
112. Raftery T, O’Sullivan M. Optimal vitamin D levels in Crohn’s disease:a review. Proc Nutr Soc. 2015;74:56–66.
113. Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases:who, in what form, and how much? J Crohns Colitis. 2015;9:198–209.
114. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol. 2007;13:4798–4806.
115. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–2552.
116. Mehra T, Seifert B, Bravo-reiter S, et al. Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. Transfusion. 2015;55:2807–2815.